Bristol-Myers Squibb Co (LIM:BMY) Total Receivables: $12,083 Mil (As of Mar. 2026)


LIM:BMY Bristol-Myers Squibb Co LIM:BMY
57 GF Score
Price $56.98
GF Value $48.23
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Total Receivables?

Bristol-Myers Squibb Co LIM:BMY 57 Total Receivables is $12,083 Mil as of Mar. 2026. GuruFocus rates LIM:BMY with a GF Score™ of 57/100 and a GF Value™ of $48.23 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Bristol-Myers Squibb Co's Total Receivables for the quarter that ended in Mar. 2026 was $12,083 Mil.

Bristol-Myers Squibb Co Total Receivables Related Terms

Bristol-Myers Squibb Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Total Receivables Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,516.00 13,937.00 15,264.00 14,424.00 14,525.00

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14,586.00 15,101.00 14,616.00 14,525.00 12,083.00
LIM:BMY
57GF Score
Bristol-Myers Squibb Co LIM:BMY
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $12,083 Mil mean?
Bristol-Myers Squibb Co (LIM:BMY) has a Total Receivables of $12,083 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's Total Receivables too high?
Bristol-Myers Squibb Co's current Total Receivables is $12,083 Mil. Overall, Bristol-Myers Squibb Co has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Total Receivables compare to PFE and GILD?
Bristol-Myers Squibb Co's Total Receivables of $12,083 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Total Receivables is $12,083 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (LIM:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is $48.23, compared to a current price of $56.98 — trading 18.1% above its estimated fair value. The current Total Receivables is $12,083 Mil. Bristol-Myers Squibb Co's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Bristol-Myers Squibb Co (LIM:BMY), the current Total Receivables is $12,083 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (LIM:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of $56.98 is trading 18.1% above its estimated GF Value™ of $48.23. GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.

Key valuation signals for LIM:BMY:

  • Total Receivables: $12,083 Mil
  • GF Value™: $48.23 vs. price of $56.98 (18.1% above fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the LIM:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
57GF Score

Get the complete analysis for LIM:BMY

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$56.98
Price
$48.23
GF Value